{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Poly+ICLC&page=2",
    "query": {
      "intervention": "Poly ICLC",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Poly+ICLC&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T23:49:37.823Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03162562",
      "title": "The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer of Ovary",
        "Neoplasms, Ovarian",
        "Ovarian Cancer Stage IV",
        "Ovarian Cancer Recurrent",
        "Ovarian Cancer Stage III",
        "Ovary Cancer"
      ],
      "interventions": [
        {
          "name": "Oregovomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Poly ICLC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "CanariaBio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 90 Years · Female only"
      },
      "enrollment_count": 10,
      "start_date": "2017-05-30",
      "completion_date": "2020-11-05",
      "has_results": false,
      "last_update_posted_date": "2020-12-22",
      "last_synced_at": "2026-09-04T23:49:37.823Z",
      "location_count": 2,
      "location_summary": "Orlando, Florida • Richmond, Virginia",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03162562"
    },
    {
      "nct_id": "NCT02643303",
      "title": "A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma",
        "Breast Cancer",
        "Sarcoma",
        "Merkel Cell Carcinoma",
        "Cutaneous T-Cell Lymphoma",
        "Melanoma",
        "Renal Cancer",
        "Bladder Cancer",
        "Prostate Cancer",
        "Testicular Cancer",
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        },
        {
          "name": "Poly-ICLC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ludwig Institute for Cancer Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2016-12-28",
      "completion_date": "2022-02-23",
      "has_results": true,
      "last_update_posted_date": "2022-12-02",
      "last_synced_at": "2026-09-04T23:49:37.823Z",
      "location_count": 7,
      "location_summary": "Atlanta, Georgia • Lebanon, New Hampshire • Buffalo, New York + 4 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02643303"
    },
    {
      "nct_id": "NCT03262103",
      "title": "Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Intratumoral (IT) Poly ICLC 0.5 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Intratumoral (IT) Poly ICLC 1.0 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Intramuscular (IM) Poly ICLC",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Radical Prostatectomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Ashutosh Kumar Tewari",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 13,
      "start_date": "2017-06-16",
      "completion_date": "2022-05-06",
      "has_results": false,
      "last_update_posted_date": "2022-09-10",
      "last_synced_at": "2026-09-04T23:49:37.823Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03262103"
    },
    {
      "nct_id": "NCT02126579",
      "title": "Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Metastatic Melanoma",
        "Mucosal Melanoma"
      ],
      "interventions": [
        {
          "name": "Peptide Vaccine (LPV7) + Tetanus peptide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PolyICLC",
          "type": "OTHER"
        },
        {
          "name": "Resiquimod",
          "type": "OTHER"
        },
        {
          "name": "IFA",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Craig L Slingluff, Jr",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2014-05-01",
      "completion_date": "2021-05-05",
      "has_results": true,
      "last_update_posted_date": "2024-02-28",
      "last_synced_at": "2026-09-04T23:49:37.823Z",
      "location_count": 2,
      "location_summary": "Houston, Texas • Charlottesville, Virginia",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02126579"
    },
    {
      "nct_id": "NCT01204684",
      "title": "Dendritic Cell Vaccine for Patients With Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioma",
        "Anaplastic Astrocytoma",
        "Anaplastic Astro-oligodendroglioma",
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "autologous tumor lysate-pulsed DC vaccination",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tumor lysate-pulsed DC vaccination+0.2% resiquimod",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tumor-lysate pulsed DC vaccination +adjuvant polyICLC",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 24,
      "start_date": "2010-10-08",
      "completion_date": "2024-08-21",
      "has_results": false,
      "last_update_posted_date": "2024-08-28",
      "last_synced_at": "2026-09-04T23:49:37.823Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01204684"
    },
    {
      "nct_id": "NCT05457959",
      "title": "Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Hemispheric Glioma, H3 G34-Mutant"
      ],
      "interventions": [
        {
          "name": "Dendritic Cell Tumor Peptide Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Leukapheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo Administration",
          "type": "DRUG"
        },
        {
          "name": "Poly ICLC",
          "type": "DRUG"
        },
        {
          "name": "Resection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "13 Years to 60 Years"
      },
      "enrollment_count": 0,
      "start_date": "2024-12-01",
      "completion_date": "2030-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-02-24",
      "last_synced_at": "2026-09-04T23:49:37.823Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05457959"
    },
    {
      "nct_id": "NCT02886065",
      "title": "A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Smoldering Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Hiltonol",
          "type": "DRUG"
        },
        {
          "name": "Citarinostat",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "PVX-410",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2017-03-07",
      "completion_date": "2026-09-15",
      "has_results": false,
      "last_update_posted_date": "2026-03-13",
      "last_synced_at": "2026-09-04T23:49:37.823Z",
      "location_count": 6,
      "location_summary": "Boston, Massachusetts • New York, New York • Durham, North Carolina + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02886065"
    },
    {
      "nct_id": "NCT02549833",
      "title": "Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Oligodendroglioma",
        "Astrocytoma, Grade II",
        "Glioma, Astrocytic",
        "Glioma",
        "Malignant Glioma",
        "Oligoastrocytoma, Mixed"
      ],
      "interventions": [
        {
          "name": "GBM6-AD and poly-ICLC before and after surgery",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GBM6-AD and poly-ICLC after surgery only",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Jennie Taylor",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2016-10-17",
      "completion_date": "2024-08-31",
      "has_results": false,
      "last_update_posted_date": "2024-11-22",
      "last_synced_at": "2026-09-04T23:49:37.823Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02549833"
    },
    {
      "nct_id": "NCT01718899",
      "title": "Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Smoldering Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "PVX-410",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "OncoPep, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "18 Years to 95 Years"
      },
      "enrollment_count": 22,
      "start_date": "2012-11",
      "completion_date": "2016-09",
      "has_results": false,
      "last_update_posted_date": "2016-09-28",
      "last_synced_at": "2026-09-04T23:49:37.823Z",
      "location_count": 6,
      "location_summary": "Atlanta, Georgia • Niles, Illinois • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Niles",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01718899"
    },
    {
      "nct_id": "NCT02510950",
      "title": "Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Astrocytoma, Grade IV"
      ],
      "interventions": [
        {
          "name": "Personalized peptide vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Poly-ICLC",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2015-12-03",
      "completion_date": "2017-02-14",
      "has_results": false,
      "last_update_posted_date": "2017-11-17",
      "last_synced_at": "2026-09-04T23:49:37.823Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02510950"
    }
  ]
}